Macrophage-targeted anti–PD-L1 therapy has been shown to increase IFN-γ production by NK cells (142), while anti–PD-1 treatment in osteosarcoma models expands the anti-tumour macrophage population (143). The gene discussed is IFNG; the disease is neoplasm.